ETP for Pharma Plants — Cost, Fumes and Vendor Checklist

An ETP for a pharma plant costs more per kilolitre than a sewage plant of the same flow because it is bought for load and toxicity, not for volume: batch-process effluent swings in strength and composition, solvents push COD up and can kill the biology, and volatile solvents create fumes around open tanks that must be designed out, not vented. Before signing with a vendor, run a checklist that forces treatability testing, load-based design and explicit fume management — the details below.

Why is pharma effluent harder to treat than ordinary industrial effluent?

Variability and toxicity. Pharmaceutical manufacturing is largely batch production: reactors are emptied, cleaned and refilled, so wastewater flows, pollutant types and concentrations change with every campaign. Industry treatment literature lists the typical challenges directly — variable flows from batch production, the risk of toxic and persistent substances, and high organic content from solvents such as alcohols, glycols, acetone, methanol and isopropanol, with more than 30 solvents in regular use across the industry (Veolia Water Technologies pharmaceutical wastewater guide). Reaction residues also carry acids, bases, metals, halides and API traces.

The toxicity problem is measurable, not theoretical. A published study of a biological pharmaceutical wastewater treatment plant found removal of 91.8% for TSS and 86.8% for BOD — yet only 72.3% for COD — with BOD and COD still above permissible limits in the treated water, and antibiotics and other emerging pollutants passing through largely untouched (Heliyon, 2024). Another study cited in that review achieved very high COD removal while removing less than 10% of two antibiotics. In other words, a plant can look healthy on BOD and still be failing on the parameters that matter for a pharma discharge — which is why treatability testing at the design stage is non-negotiable.

Formulation (fill-and-finish) plants are the milder case: rinse water carries starches, sugars and detergents, which are biodegradable, though detergents cause foaming. API and chemical-synthesis plants are the hard case: solvent-heavy, pH-variable, sometimes salty, with API traces needing specific treatment steps.

What actually drives the cost of a pharma ETP?

The honest answer: load, pretreatment and compliance, in that order. Two plants with the same KLD flow can differ several-fold in price because the design driver is kilograms of COD per day, not litres. The factors to interrogate in any quote:

• Organic load, not flow. Solvent-rich effluent carries COD far above sewage levels; every increment of load buys aeration volume, blower capacity and tankage.
• Toxicity pretreatment. Where effluent inhibits biomass, the treatment train grows: neutralisation, solvent stripping or recovery, advanced oxidation or activated carbon ahead of (or after) biology. Each stage is capital and chemicals.
• Equalisation capacity. Batch discharges need enough tankage to spread a campaign slug over a day or more — underbuying here is the classic cause of a pharma ETP that passes commissioning and fails in production.
• Materials and covers. Salty, acidic or solvent-laden streams demand corrosion-resistant materials and covered, ventilated tanks — both real money.
• Monitoring and compliance. Continuous online effluent monitoring connectivity to board servers, lab setup and consent conditions add fixed costs regardless of plant size.
• Automation and O&M. A plant that runs unattended shifts costs more up front in instruments and less down the line in failures — the trade should be priced, not defaulted.

As for price levels: published vendor ranges are wide. One environmental contractor publishes a starting price of ₹14.5 lakh for compact pharma ETPs around 20–30 KLD (Richa Environmental), while vendor commentary on Indian ETP pricing notes quotes of ₹18 lakh and ₹32 lakh for plants both described as 100 KLD (Hydromo, LinkedIn). Treat any per-KLD price you are given as indicative only — two quotes for the same KLD can differ nearly two-fold because they assume different loads. Model your own payback with a ROI calculator and insist quotes are broken down by load assumption. Our ETP cost and manufacturer guide covers the market landscape in detail.

Why does a pharma ETP smell or fume, and what fixes it?

Three distinct causes, each with a different fix:

• Solvent vapours (the pharma-specific one). Volatile solvents entering an open aeration tank are stripped into the air by the bubbling itself — the same property that makes low-boiling-point solvents impossible to remove by evaporation without them turning up in the distillate (Veolia guide). Fumes around an ETP are therefore usually solvents leaving the water, not odorous biology. Fixes: recover or segregate solvent-bearing streams at source; cool hot streams before aeration; cover the equalisation and aeration tanks and route headspace through a scrubber or activated carbon — the same scrubbers whose blowdown returns to the ETP as a monitored stream.
• Septic odour (hydrogen sulphide). Stagnant collection sumps, undersized equalisation or overloaded biology turn anaerobic and smell of rotten eggs. Fixes are conventional: aeration, turnover, desludging discipline.
• Chemical odour and foaming. Detergent-bearing rinse water foams and carries smell across the plant. Fixes: antifoam discipline plus source segregation of detergent streams, and checking that foam is not masking a loading problem.

One safety note that goes beyond nuisance: solvent slugs in closed tanks can create flammable vapour spaces. Covered tanks on pharma ETPs need ventilation and, where solvent loads are real, electrical equipment rated for the zone. Ask any vendor directly how their cover-and-vent design handles this; a vague answer is a finding.

What discharge limits will a pharma ETP have to meet?

The general standards for discharge of effluents under the Environment (Protection) Rules apply — BOD 30 mg/L, COD 250 mg/L, suspended solids 100 mg/L, oil and grease 10 mg/L and pH 5.5–9 for discharge to inland surface water (CPCB general discharge standards) — and pharmaceutical-specific standards tighten the BOD measurement basis and conditions further for bulk-drug and formulation plants. The binding numbers for your unit are set by your State Pollution Control Board consent, which may also require online monitoring to board servers; our guide to the CPCB OCEMS mandate explains that side. Design margin should target the stricter limit, because COD compliance is exactly where pharma effluent strains a biological plant.

Vendor checklist for a pharma ETP

Run every vendor through these questions before comparing prices:

1. Treatability evidence, not assumptions. Has the vendor run or proposed characterisation and bench or pilot tests on your actual effluent? Industry practice treats questionnaire, laboratory, bench and pilot testing as distinct mandatory steps for pharma (Veolia guide). A design based only on KLD figures is a red flag.
2. Load-based design. Is the design stated in kg COD/day and kg BOD/day, with the batch profile, solvent inventory and campaign schedule documented?
3. Toxicity plan. What happens when a toxic batch slug arrives — equalisation volume, neutralisation, inhibition monitoring, and a route for rejecting or bleeding high-toxicity streams slowly?
4. Fume and VOC design. Which tanks are covered, where does headspace go, and is the equipment rated for solvent vapour spaces?
5. Emerging-pollutant strategy. If APIs must be reduced in the effluent, which tertiary step (advanced oxidation, activated carbon, membrane) is proposed, and what removal evidence supports it? Remember that conventional biology removes very little of some antibiotics (Heliyon, 2024).
6. Compliance scope. Does the quote include online effluent monitoring integration, lab establishment, and consent-condition support — or are those priced separately later?
7. Reference plants. Which pharma installations can be visited or verified publicly? (Our pharma and healthcare page lists relevant work.)
8. O&M offer. Is there an AMC with daily process logging — pH, DO, MLSS, inlet COD trend — because pharma ETPs fail on drift, not on disaster? Also compare against our general ETP/STP contractor questions.
9. Sludge and residue route. Pharmaceutical ETP sludge is typically hazardous waste; the quote should include classification, dewatering and disposal through authorised channels.

Frequently asked questions

What size ETP does a pharma plant need?

Formulation plants typically need compact plants in the tens of KLD; API synthesis plants need sizing driven by COD load and batch equalisation, and can reach hundreds of KLD. A characterisation study, not a rule of thumb, should fix the number — vendor capacity tables list pharma plants anywhere from about 10 to 250 KLD (Varuna Eco).

Why did our ETP pass commissioning but fail in production?

Batch pharma production means commissioning was likely run on mild, diluted or synthetic streams. The first full-strength solvent campaign then shocks the biology. Adequate equalisation, source segregation and an operator trained on the batch schedule prevent this.

Can biological treatment alone handle API effluent?

Often not entirely. Biology handles the biodegradable organics well, but studies show antibiotics and other emerging pollutants pass through conventional biological plants almost untouched, and COD can remain above limits (Heliyon, 2024). A polish step or dedicated API reduction is commonly needed before discharge.

How do we stop fumes around the ETP?

Recover or segregate solvents at source, cool hot streams, and cover aerated tanks with headspace routed to a scrubber or activated carbon. Masking fragrances are not a fix, and uncontrolled solvent vapour is a safety issue as well as an odour one.

Is ZLD required for pharma plants?

Increasingly, yes, where consents or water-stress conditions demand zero liquid discharge — pharma is one of the industries most frequently pushed toward ZLD because of its effluent character. It is a separate design decision from the ETP itself, driven by your consent and reuse targets.

What should a quoted price include?

At minimum: design on stated kg COD/day, all pretreatment stages, covers and ventilation, monitoring and consent support, sludge handling, commissioning with your actual effluent, and an O&M option. Anything excluded should be priced as a line item, not discovered after purchase.

Closing

A pharma ETP is bought with data: a characterisation of your effluent, a load-based design, an explicit fume plan and a vendor who proves treatability before quoting. Navbharat Water designs, builds and operates effluent treatment plants for pharma and healthcare manufacturing — see our healthcare and pharma industry page and effluent treatment solutions. To have an engineer review your effluent characterisation and vendor quotes, contact our engineers or get a quote.

Sources

• Veolia Water Technologies — Pharmaceutical Manufacturing Wastewater Treatment Guide (2020) — batch variability, solvents (30+ in regular use), toxic/persistent substance risks, volatile solvent behaviour, scrubber blowdown, detergents causing foam, testing methodology (questionnaire/lab/bench/pilot).
• Heliyon (PMC) — Factors affecting the performance of a pharmaceutical wastewater treatment plant, 2024 — measured removal efficiencies (TSS 91.8%, BOD 86.8%, COD 72.3%), treated water above limits, antibiotics removed poorly by biological plants.
• CPCB — General Standards for Discharge of Environmental Pollutants, Effluents (Environment Protection Rules, Schedule VI) — BOD 30 mg/L, COD 250 mg/L, TSS 100 mg/L, oil and grease 10 mg/L, pH 5.5–9 for inland surface water discharge.
• Richa Environmental — ETP 20/25/30 KLD cost page — vendor-published starting price of ₹14.5 lakh for compact pharma ETPs (reported, vendor pricing).
• Varuna — ETP Explained: Cost, Capacity, Compliance — pharma ETP capacity range ~10–250 KLD (reported, vendor publication).